C. difficile

FDA approves first oral microbiome therapy Vowst
FDA approves first oral microbiome therapy Vowst
Fierce Pharma
Seres Therapeutics
microbiome
Vowst
SER-109
C. difficile
FDA
Flag link:
Vedanta Raises $106.5M to Advance New Class of C.diff Therapeutics
Vedanta Raises $106.5M to Advance New Class of C.diff Therapeutics
BioSpace
Vedanta Biosciences
funding
C. difficile
VE303
Flag link:
5 FDA decisions to watch in the second quarter
5 FDA decisions to watch in the second quarter
BioPharma Dive
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Biogen
tofersen
ALS
Seres Therapeutics
C. difficile
Pfizer
GSK
vaccines
RSV
Regeneron
Eylea
Flag link:
FDA approves first fecal microbiome drug, setting stage for others
FDA approves first fecal microbiome drug, setting stage for others
Stat
Ferring Pharmaceuticals
Rebyota
FDA
C. difficile
fecal microbiome
microbiome
Flag link:
Seres one step closer to bringing first oral microbiome therapy to market as FDA mulls approval
Seres one step closer to bringing first oral microbiome therapy to market as FDA mulls approval
Fierce Biotech
Seres Therapeutics
microbiome
C. difficile
SER-109
Flag link:
FDA panel recommends Ferring's fecal transplant therapy
FDA panel recommends Ferring's fecal transplant therapy
NASDAQ
Ferring Pharmaceuticals
fecal transplants
C. difficile
FDA
Flag link:
One week after Takeda walked away, Finch faces second round of layoffs, pipeline pruning
One week after Takeda walked away, Finch faces second round of layoffs, pipeline pruning
Endpoints
Finch Therapeutics
Takeda
layoffs
C. difficile
Flag link:
FDA's vaccine adcomm to review first fecal transplant to treat C. difficile infections
FDA's vaccine adcomm to review first fecal transplant to treat C. difficile infections
Endpoints
FDA
Ferring Pharmaceuticals
Rebiotix
RBX2660
C. difficile
Flag link:
Summit will take scenic route up FDA mountain after regulator recommends more trials for C. diff therapy
Summit will take scenic route up FDA mountain after regulator recommends more trials for C. diff therapy
Fierce Biotech
Summit Therapeutics
ridinilazole
C. difficile
Flag link:
Plotting a comeback after 2016 flop, Seres to raise $100M to prep C. difficile program for launch
Plotting a comeback after 2016 flop, Seres to raise $100M to prep C. difficile program for launch
Endpoints
Seres Therapeutics
microbiome
C. difficile
funding
Flag link:
Seres, Vera Notch Weekend Wins in C.Diff, Lupus Trials
Seres, Vera Notch Weekend Wins in C.Diff, Lupus Trials
BioSpace
Seres Therapeutics
clinical trials
SER-109
C. difficile
Vera Therapeutics
lupus
atacicept
Flag link:
FDA lifts hold on Finch’s microbiome crapsule, as company looks to right ship
FDA lifts hold on Finch’s microbiome crapsule, as company looks to right ship
Endpoints
Finch Therapeutics
FDA
microbiome
crapsules
clinical trials
C. difficile
Flag link:
Finch clips wings of hepatitis B program, hitting pause on clinical plan to focus on C. diff and autism
Finch clips wings of hepatitis B program, hitting pause on clinical plan to focus on C. diff and autism
Fierce Biotech
Finch Therapeutics
hepatitis B
microbiome
clinical trials
autism
C. difficile
Flag link:
The year the regulators meet the microbiome
The year the regulators meet the microbiome
EP Vantage
microbiome
Seres Therapeutics
Ferring Pharmaceuticals
FDA
C. difficile
Flag link:
Summit says path forward for failed C. difficile drug is likely through partnerships
Summit says path forward for failed C. difficile drug is likely through partnerships
Fierce Biotech
Summit Therapeutics
Vancomycin
clinical trials
C. difficile
Flag link:
FDA slaps hold on Finch's C. diff med to get info on COVID-19 screening for donor-derived therapy
FDA slaps hold on Finch's C. diff med to get info on COVID-19 screening for donor-derived therapy
Fierce Biotech
Finch Therapeutics
C. difficile
clinical hold
FDA
clinical trials
microbiome
Flag link:
Pfizer seeks silver lining in failed C. diff vaccine trial
Pfizer seeks silver lining in failed C. diff vaccine trial
Pharmaforum
Pfizer
vaccines
clinical trials
C. difficile
Flag link:
Pfizer fails phase 3 C. diff vaccine test but still spies possible path forward
Pfizer fails phase 3 C. diff vaccine test but still spies possible path forward
Fierce Biotech
Pfizer
clinical trials
vaccines
C. difficile
Flag link:
Vedanta brings home a win for lead microbiome program, passing a PhII test and clinching BARDA investment
Vedanta brings home a win for lead microbiome program, passing a PhII test and clinching BARDA investment
Endpoints
Vedanta Biosciences
microbiome
clinical trials
C. difficile
BARDA
Flag link:
CRISPR Technology Edges Closer to Commercial Use
CRISPR Technology Edges Closer to Commercial Use
BioSpace
CRISPR
C. difficile
Flag link:

Pages